[HTML][HTML] Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis
Background Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA;
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. Methods …
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. Methods …
[引用][C] Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
F De Benedetti, HI Brunner, N Ruperto… - New England Journal …, 2012 - cir.nii.ac.jp
Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲ恁縖サイニィ] 詳細へ移動 検索フォ恁啶匾動 論文·デ恁郡 …
CiNii 国立情報学研究所 学術情報ナビゲ恁縖サイニィ] 詳細へ移動 検索フォ恁啶匾動 論文·デ恁郡 …
[引用][C] Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
F DE BENEDETTI, HI BRUNNER… - The New England …, 2012 - pascal-francis.inist.fr
Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis CNRS Inist Pascal-Francis
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis
F De Benedetti, HI Brunner, N Ruperto… - NEW ENGLAND …, 2012 - biblio.ugent.be
BACKGROUND Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA;
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA …
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA …
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis
F De Benedetti, HI Brunner, N Ruperto… - NEW ENGLAND …, 2012 - research.unipd.it
BACKGROUND: Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA;
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA …
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA …
[PDF][PDF] Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
MD Fabrizio De Benedetti, HI Brunner, N Ruperto… - N Engl J Med, 2012 - uab.edu
Results At week 12, the primary end point (an absence of fever and an improvement of 30%
or more on at least three of the six variables in the American College of Rheumatology …
or more on at least three of the six variables in the American College of Rheumatology …
[PDF][PDF] Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
MD Fabrizio De Benedetti, HI Brunner, N Ruperto… - N Engl J …, 2012 - researchgate.net
Results At week 12, the primary end point (an absence of fever and an improvement of 30%
or more on at least three of the six variables in the American College of Rheumatology …
or more on at least three of the six variables in the American College of Rheumatology …
[PDF][PDF] Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
MD Fabrizio De Benedetti, HI Brunner, N Ruperto… - N Engl J Med, 2012 - academia.edu
Results At week 12, the primary end point (an absence of fever and an improvement of 30%
or more on at least three of the six variables in the American College of Rheumatology …
or more on at least three of the six variables in the American College of Rheumatology …
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
F De Benedetti, HI Brunner, N Ruperto… - The New England …, 2012 - europepmc.org
Background Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA;
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. Methods …
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. Methods …
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis
F De Benedetti, HI Brunner… - The New England …, 2012 - pubmed.ncbi.nlm.nih.gov
Background Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA;
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. Methods …
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. Methods …